Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOP-ILD study of nintedanib with tacrolimus and prednisolone in untreated progressive pulmonary fibrosis
jRCTs071230004Phase 2Completed
- Sponsor
- Kakihara Science and Technology Research Foundation
- Start
- May 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nintedanib, tacrolimus and prednisolone in pulmonary fibrosis (PF), sponsored by Kakihara Science and Technology Research Foundation. Primary endpoint: Change in rate of decline in percent predicted FVC before and 24 weeks after treatment. Started May 2023; status: completed.
02
Drugs
nintedanibtacrolimusprednisolone
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on jRCTs071230004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071230004.